Management of the middle hepatic vein in right lobe living donor liver transplantation: A meta-analysis.
10.1007/s11596-015-1477-3
- Author:
Peng-Sheng YI
1
;
Ming ZHANG
;
Ming-Qing XU
Author Information
1. Department of Liver Surgery, West China Hospital of Sichuan University, Chengdu, 610041, China, 15208207079@163.com.
- Publication Type:Journal Article
- MeSH:
Adult;
Databases, Bibliographic;
Female;
Graft Survival;
Hepatic Veins;
surgery;
Humans;
Liver;
blood supply;
physiology;
Liver Transplantation;
Living Donors;
Male;
Middle Aged;
Observational Studies as Topic;
Prognosis
- From:
Journal of Huazhong University of Science and Technology (Medical Sciences)
2015;35(4):600-605
- CountryChina
- Language:English
-
Abstract:
Living donor liver transplantation (LDLT) is a curative treatment for end stage liver disease. It is advantageous due to the shortage of deceased donors. However, in LDLT, whether the middle hepatic vein (MHV) should be preserved in donors remains controversial. We conducted searches in Pubmed, Embase, Cochrane Library, Web of Science, Ovid, and Google Scholar using the key words "living donor liver transplantation" and "middle hepatic vein". Due to ethical issues, there were no randomized control trails focusing on MHV in LDLT. The majority of reports were retrospective studies. We examined the reference lists to identify related investigations. Google Scholar was then used to obtain full texts. Nine observational studies were analyzed. There were no significant differences in liver function (WMD, -5.51; P=0.12) and complications (RR, 0.98; P=0.89) in donors with or without MHV. However, the liver function in recipients was greatly improved after LDLT with MHV (WMD, -78.32; P=0.01). No definite conclusion was obtained in terms of the liver regeneration indices between LDLT with or without MHV. It was conclude that grafts with MHV in LDLT favor recipient outcomes and do not harm the living donor if a careful preoperative evaluation is performed.
